Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease
| Autor: | Seema Kumar, Rachel Chevalier, Felicity Enders, Leonard A. Haas, Brittny Major, Jeanne Tung |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Pediatric Obesity Time Factors Side effect Adolescent Physiology Excess weight Overweight Weight Gain Gastroenterology Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Excessive weight gain Crohn Disease Gastrointestinal Agents Risk Factors Internal medicine medicine Humans Age of Onset Child Retrospective Studies 030203 arthritis & rheumatology Crohn's disease Biological Products Anthropometric data business.industry Tumor Necrosis Factor-alpha Hepatology medicine.disease Ulcerative colitis Infliximab Biologic Agents Treatment Outcome Child Preschool 030211 gastroenterology & hepatology Colitis Ulcerative Female Underweight medicine.symptom business medicine.drug |
| Zdroj: | Digestive diseases and sciences. 62(11) |
| ISSN: | 1573-2568 |
| Popis: | Children with active inflammatory bowel disease (IBD) are frequently underweight. Anti-tumor necrosis factor (anti-TNF) agents may induce remission and restore growth. However, its use in other autoimmune diseases has been associated with excess weight gain. Our aim was to examine whether children with IBD could experience excess weight gain.A centralized diagnostic index identified pediatric IBD patients evaluated at our institution who received anti-TNF therapy for at least 1 year between August 1998 and December 2013. Anthropometric data were collected at time of anti-TNF initiation and annually. Excess weight gain was defined as ΔBMI SDS (standard deviation score) where patients were (1) reclassified from "normal" to "overweight/obese," (2) "overweight" to "obese," or (2) a final BMI SDS0 and ΔSDS0.5.During the study period, 268 children received anti-TNF therapy. Of these, 69 had sufficient follow-up for a median of 29.3 months. Median age at first anti-TNF dose was 12.8 years. At baseline, mean weight SDS was -0.7 (SD 1.4), while mean BMI SDS was -0.6 (1.3). Using baseline BMI SDS, 11.6% were overweight/obese. At last follow-up (LFU), however, the mean ΔBMI SDS was 0.50 (p 0.0001). However, 10 (17%) patients had excess weight gain at LFU; 3 patients were reclassified from "normal" to "obese," and 7 had a final BMI SDS0 and ΔSDS0.5.Pediatric patients with IBD may experience excess weight gain when treated with anti-TNF agents. Monitoring for this side effect is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink